Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors

Blood Cancer Clinical Trial

Official title:

Stem Cell Transplantation From Matched Unrelated or Partially Matched Related Donors Using a Preparatory Regimen Consisting of Fractionated Total Body Irradiation (FTBI) and Cyclophosphamide (CY)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00186225
• Other study ID #: IRB-13390
• Secondary ID: 75268BMT22
• Status: Completed
• Phase: N/A
• Start date: November 1989
• Est. completion date: May 2010

Study information

• Verified date: April 2020
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the use of unrelated donors for hematopoietic cell transplantation in the treatment of hematologic and lymphoid malignancies.

Description:

Stem Cell Transplantation from Matched Unrelated or Partially Matched Related Donors Using a Preparatory Regimen Consisting of Fractionated Total Body Irradiation (FTBI) and Cyclophosphamide (CY). To administer high dose radio-chemotherapy followed by stem cell transplantation from a matched unrelated donor or a partially matched related donor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 250
• Est. completion date: May 2010
• Est. primary completion date: June 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 50 Years

Eligibility

Inclusion Criteria:- acute leukemia

• chronic leukemia

• lymphoblastic lymphoma

• MDS

• MPS Exclusion Criteria:- organ dysfunction

• HIV positive

Related Conditions & MeSH terms

• Blood and Marrow Transplant (BMT)
• Blood Cancer
• Hematologic Neoplasms

Intervention

Procedure:
• ablative allogeneic hematopoietic cell transplantation

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	oxicity and efficacy of TBI and cyclophosphamide as preparation for hematopoietic cell transplantation from partially matched and unrelated donors.
Secondary	Overall Survival
Secondary	Event Free Survival